Anticorps monoclonaux - activities

Covid: Xenothera's therapy, Xav-19, working against Omicron

And what if, amid the fight against Covid, one could rely – in addition to the upcoming vaccine – on antibody-based treatments? After Bamlanivimab – the treatment developed by the Eli Lilly laboratory – or even Regeneron, this is now French Nantes-based laboratory Xenothera’s turn to present a treatment undergoing clinical trials, Xav-19. According to primary studies, the therapy is effective against Covid's Omicron variant, but waiting for the green light for marketing from early 2022.

Coronavirus: an AstraZeneca antibody therapy approved by the Haute Autorité de Santé

This Friday December 10, the Haute Autorité de Santé announced they have approved the use of Evusheld (tixagevimab-cilgavimab), a coronavirus monoclonal antibody-based therapy developed by AstraZeneca. But the therapy includes cardiovascular risks… Here is more on the matter.

Covid: antibody cocktail Regeneron working up to eight months, the laboratory claims

Good news in the search for the fight against Covid… Regeneron announced their antibody cocktail injected in cases of severe disease was 80% effective for at least eight months, according to the drugmaker’s latest studies. It involves a cocktail of antibodies given in 2020 to U.S. President Trump when we was hospitalized for severe covid.

Covid: fluvoxamine, the antidepressant likely to cut down hospitalization risks, studies found

There is a potential new Covid drug! Following preliminary results from a Canadian study released this past August, the results of a Brazilian clinical results issued this late October in The Lancet seem to confirm antidepressant fluvoxamine considerably decreases hospitalization risk for people contaminated.

Covid: a new antibody therapy developed by Spiklmm under rolling review

Is a new Covid therapy based on monoclonal antibodies soon to be reviewed? This is what infectious disease specialist and member of Spiklmm biotech administration board Karine Lacombe has explained. The very laboratory is developing this therapy. Clinical trials are expected to start from the beginning of 2022.

Covid: Ronapreve, the preventive antibody therapy for immunocompromised people approved by the HAS

Less protected against coronavirus, immunocompromised people will be allowed to get a preventive Covid-19 therapy based on monoclonal antibodies, the Haute Autorité de Santé stated.

Covid: why is looking for a therapy more difficult than for a vaccine?

As several Covid vaccines are being given in the whole world, over 1.5 year of pandemic, the search for therapies is still groping around. Why is looking for a coronavirus therapy more difficult? Food for thoughts…

Coronavirus: The European Union ordered a new antibody therapy

This Wednesday July 28, the European Union announced they have secured a deal for a new experimental coronavirus therapy, Sotrovimab, developed by UK laboratory GSK. A promising monoclonal antibody therapy.

Covid: effectiveness of monoclonal antibodies challenged by variants

As Covid variants keep on spreading across the world, Eli Lilly laboratories has seen their approval removed for marketing bamlanivimab, as a monotherapy, being a therapy based on monoclonal antibodies. Why? Its effectiveness challenged by new coronavirus strains. Keep reading to find out more!

Covid: France has approved two monoclonal antibody therapies

This Monday March 15, the Agence du Médicament (French Medicines Agency) announced that two monoclonal antibody therapies, namely REGN-COV2 and Eli Lilly laboratory's therapy based on bamlanivimab and etesevimab were now approved in France.